Poor Outcome of Myeloablative Conditioned Allogeneic Bone Marrow Transplantation for Myelofibrosis
スポンサーリンク
概要
- 論文の詳細を見る
Objective This study retrospectively analyzed clinical outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelofibrosis (MF) in a single institution. Methods During the past 20 years, 6 patients with MF have undergone allo-HSCT in our institution. We investigated the clinical characteristics and follow-up course of these patients. Patients Median age was 47 years (range, 40-52 years). The median interval between diagnosis and allo-HSCT was 12.5 months (range, 5-97 months). Results Among these 6 patients, 4 patients were categorized in the high-risk group according to the International Prognostic Scoring System. All 6 patients received myeloablative conditioning regimens, but most of them eventually died of relapse. Conclusion In this small series, allo-HSCT resulted in dismal outcomes. Our experience clearly indicates the need for studies with a larger series of patients to evaluate the efficacy of this modality.
著者
-
Kobayashi Takeshi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
-
Sakamaki Hisashi
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Akiyama Hideki
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Ohashi Kazuteru
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Kakihana Kazuhiko
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Yamamoto Masahide
Hematology Division Tokyo Metropolitan Cancer And Infectious Diseases Center Komagome Hospital
-
Sakamaki Hisashi
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Ohashi Kazuteru
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Hirashima Yuka
Pharmacy Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Akiyama Hideki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
-
Yamamoto Masahide
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan
関連論文
- Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR
- Use of Octreotide in the Management of Severe Duodenal Bleeding after Unrelated-Donor Bone Marrow Transplantation
- Rapidly Progressive Epstein-Barr Virus-associated Lymphoproliferative Disorder Unpredictable by Weekly Viral Load Monitoring
- Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia
- Leukemic infiltration of the lung following allogeneic hematopoietic stem cell transplantation
- Mikulicz's disease with severe thrombocytopenia following autologous stem cell transplantation in a multiple myeloma patient
- Acquired Storage-Pool Disorders Occurring Late After Allogeneic Bone Marrow Transplantation: Partial Activation of Platelets in Asymptomatic Patients
- Human Herpesvirus 6 Meningoencephalitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
- Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase
- A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease
- Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion
- Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation
- Frequent Exacerbation of Pulmonary Nocardiosis during Maintenance Antibiotic Therapies in a Hematopoietic Stem Cell Transplant Recipient
- Immune-Mediated Myelopathy following Allogeneic Stem Cell Transplantation
- Granulocyte Colony-Stimulating Factor-Primed Donor Lymphocyte Infusion after Salvage Chemotherapy for Treatment of Relapsed Acute Leukemia after Allogeneic Stem Cell Transplantation
- Cytogenetic Abnormalities without Evidence of Relapse after Treatment with Imatinib and Stem Cell Transplantation in a Patient with Ph-Positive ALL
- Hepatitis B Virus Reactivation in a Patient With Chronic GVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
- Imatinib Mesylate (Gleevec) in the Treatment of 2 Patients with Philadelphia-Positive ALL Relapsing after Allogeneic Stem Cell Transplantation
- Erythrocytosis caused by erythropoietin-producing thymic carcinoma
- Low-Dose Antithymocyte Globulin for Treatment of Steroid-Pulse-Resistant Acute Graft-versus-Host Disease
- Effect of Additional Chromosomal Abnormalities in Acute Promyelocytic Leukemia Treated With All-trans-Retinoic Acid: A Report of 17 Patients
- Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia : a retrospective safety analysis
- Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population
- Osteonecrosis of the humeral head
- Ocular palsy associated with aggressive NK-cell leukemia
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
- Risk Assessment for Acute Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation Based on Acute Kidney Injury Network Criteria
- Poor Outcome of Myeloablative Conditioned Allogeneic Bone Marrow Transplantation for Myelofibrosis
- Bortezomib-induced Posterior Reversible Encephalopathy Syndrome in a Patient with Newly Diagnosed Multiple Myeloma
- Spontaneous Huge Hematoma in the Abdominal Wall after Lenalidomide
- Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin
- Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan
- Acquired Factor X Deficiency Associated with Atypical AL-amyloidosis
- Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study